[go: up one dir, main page]

WO2000062753A1 - Preparations pharmaceutiques ou cosmetiques pour l'application locale intradermique d'hormones - Google Patents

Preparations pharmaceutiques ou cosmetiques pour l'application locale intradermique d'hormones Download PDF

Info

Publication number
WO2000062753A1
WO2000062753A1 PCT/EP2000/002999 EP0002999W WO0062753A1 WO 2000062753 A1 WO2000062753 A1 WO 2000062753A1 EP 0002999 W EP0002999 W EP 0002999W WO 0062753 A1 WO0062753 A1 WO 0062753A1
Authority
WO
WIPO (PCT)
Prior art keywords
skin
estrogen
composition according
matrix
pharmaceutical
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP2000/002999
Other languages
German (de)
English (en)
Inventor
Holger Zimmermann
Sabine Fricke
Christoph Völkel
Walter Elger
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Jenapharm GmbH and Co KG
Original Assignee
Jenapharm GmbH and Co KG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE1999118644 external-priority patent/DE19918644A1/de
Application filed by Jenapharm GmbH and Co KG filed Critical Jenapharm GmbH and Co KG
Priority to EP00926811A priority Critical patent/EP1171091A1/fr
Priority to AU45432/00A priority patent/AU4543200A/en
Priority to JP2000611890A priority patent/JP2003527310A/ja
Publication of WO2000062753A1 publication Critical patent/WO2000062753A1/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/08—Anti-ageing preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/63—Steroids; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/16—Emollients or protectives, e.g. against radiation

Definitions

  • the invention relates to pharmaceutical or cosmetic compositions for local intradermal application of estrogens
  • Est ⁇ ol is considered to be a weakly effective estrogen, i.e. the systemic activity is significantly less than that of the other estrogens.
  • Punnonen et al Punnonen R, Vaajalahti P, Teisala K, Ann Chir Gynaecol Suppl 1987, 202, 39 - 41 found that after local application, Est ⁇ ol maintains the elasticity of the skin.
  • Transdermal therapeutic systems are suitable for demanding the active ingredient through the skin in particular, possibly with the aid of penetration and / or permeation promoters. These often cause temporary damage to the upper layers of the skin, which makes their use problematic
  • DE 196 35 883 A1 describes a transdermal therapeutic system of a combination of Est ⁇ ol with one or more further active ingredients, preferably those which take advantage of the supportive effect of Est ⁇ ol in the treatment of osteoporosis, arterosclerosis and heart failure, for example beta blockers and Ca antagonists
  • WO 95/22322 describes a transdermal therapeutic system for the application of sex steroids which, in the case of Est ⁇ ol, contains penetration enhancers and installation inhibitors.
  • WO 93/18774 describes the use of Est ⁇ ol for the production of a transdermal drug continuously releasing the active ingredient for the treatment of climactic osteoporosis.
  • a pharmaceutical formulation is disclosed which ensures the complete systemic availability of Est ⁇ ol
  • EP 0 765 663 A2 describes the use of dienogest or a combination of dienogest and an estrogen for the treatment of acne vulga ⁇ s seborrhea alopecia and androgen symptoms of women with a pharmaceutical preparation which makes the active ingredient available locally and prevents systemic side effects.
  • the object of this invention is, however To provide dienogest locally, the estrogen, if necessary, only to be added as a supporting agent
  • the object is achieved in that a pharmaceutical or cosmetic composition for local, intradermal application of estrogens containing at least one estrogen in combination with a structuring agent is created in a common matrix
  • estrogen refers to steroidal or non-steroidal substances which stimulate the growth of the genital organs, which develop female sexual characteristics and which can more or less proliferate a resting endometnum, in particular human estrogens such as estrone, estradiol, estratnol, equine Estrogens such as Equihn 17 -estrad ⁇ ol, phytoestrogens such as rhaponticin, understood It is particularly advantageous if the estrogen is a synthetic or biogenic estrogen or a compound which closes off one of the abovementioned compounds rapidly after application, for example esterified estrogen such as estradiol valerate or benzoate, estrogen sulfamate conjugated estrogen such as estrone sulfate or estolol glucuride or a mixture of natural and / or synthetic estrogens , such as an extract from certain palm kernels
  • the estrogen is est ⁇ ol or ⁇ - or ⁇ -estradiol or is a compound which rapidly cleaves one of the abovementioned compounds after application
  • composition according to the invention is further characterized in that the structuring agent is selected, for example, from sucrose lactose mannitol, mannitose, succinic acid or a mixture of the aforementioned substances
  • the matrix is a molecularly disperse distribution of the estrogen in a structuring agent, the structuring agent being selected, for example, from sucrose, lactose, mannitol, mannitose succinic acid or a mixture of the aforementioned substances
  • the molecularly disperse distribution additionally contains an auxiliary which is selected, for example, from polyethylene glycols, polyvinylpyrrolidones, cellulose derivatives or mixtures thereof
  • the matrix is suspended or emulsified in a base suitable for intradermal use, such as creams, ointments, emulsions, suspensions, gels or other semi-solid systems
  • Another object of the present invention is the use of the composition according to the invention for the manufacture of a medicament, for example creams, ointments, emulsion suspensions, gels or other semi-solid systems, for the treatment of skin aging and for the reduction of wrinkles in the skin So the most important thing is. to keep the systemic effects of the hormones (estrogens) as low as possible. In this case, the systemic availability is an effect which is undesirable for local application in the skin.
  • a medicament for example creams, ointments, emulsion suspensions, gels or other semi-solid systems
  • composition according to the invention effects the permeation of estrogens through the skin, but there is no high systemic availability and action.
  • the present invention thus excellently achieves the object of providing a pharmaceutical or cosmetic preparation which allows hormones, preferably estriol, ⁇ - and ⁇ -estradiol, to penetrate the skin to a sufficient extent (penetration) and at the same time the hormone in the upper layers of skin fixed as a depot so that the hormones do not penetrate the skin completely (permeation).
  • hormones preferably estriol, ⁇ - and ⁇ -estradiol
  • the basic idea of the invention is that the preparation according to the invention enriches water in the upper layers of the skin, which serves as a depot for the hormones. This seems to enable local effectiveness, but at the same time renders penetration of the skin and thus a systemic effect impossible.
  • FIG. 1 shows that the preparation according to the invention stores more water in the upper layers of the skin, which results in a hormone depot.
  • the light areas of the fingertip (R) shown show a significantly increased signal intensity of the proton spin densities in the skin areas, which were treated with the cream, which contains structuring agents.
  • the dark areas (L) show a comparison preparation without a structuring agent, in which water is not stored and the hormone is not stored.
  • hormones preferably estrogens such as estriol or estradiol
  • a structure-forming agent of the water structure preferably a solid dispersion, a sprayed premix (premix) or a mixture of both forms.
  • the invention is illustrated by the following examples.
  • a matrix of the following composition is produced by spray drying:
  • estriol is partially amorphized compared to the starting substance and has a particle size smaller than 8 ⁇ m (50%).
  • a matrix of the following composition is produced by spray drying: Estradiol 3 parts by mass
  • estriol is amorphized compared to the starting substance and has a particle size of less than 8 ⁇ m (50%).
  • FIG. 2 shows the pharmacokinetics of estriol from a preparation according to the invention according to Example 1.
  • Example 5 The blood levels shown in FIG. 2 clearly show that the systemically available free estriol after using a preparation according to the invention according to Example 1 is in the subtherapeutic range of only up to 10 pg / ml. The permeation is therefore very weak.
  • Example 5 The blood levels shown in FIG. 2 clearly show that the systemically available free estriol after using a preparation according to the invention according to Example 1 is in the subtherapeutic range of only up to 10 pg / ml. The permeation is therefore very weak.
  • Example 2 A pharmaceutical or cosmetic preparation according to Example 1, which contained 1% estriol, was applied to the excised udder udder skin (thickness: approx. 1.0 mm, area: 1, 77 cm 2 ). The transdermal permeation was determined by means of the total permeated mass of estriol in 48 hours and the penetration by means of the content of estriol in the treated skin area. The results are shown in FIG. 3.
  • Figure 3 is a representation of the permeated and penetrated mass of estriol.
  • the mass of estriol that has penetrated the skin is 50 times higher after 48 hours than that which has permeated through the skin.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Toxicology (AREA)
  • Birds (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gerontology & Geriatric Medicine (AREA)
  • Cosmetics (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Préparations pharmaceutiques ou cosmétiques pour l'application locale intradermique d'oestrogènes, qui contiennent au moins un oestrogène en combinaison avec une substance de formation de structure dans une matrice commune. Des systèmes de ce type sous forme de crèmes, d'onguents, d'émulsions, de suspensions, de gels ou d'autres systèmes à demi-solides garantissent un séjour à long terme et à haute concentration des hormones dans la peau et empêchent les hormones de se disperser de manière systémique. Lesdites préparations servent à traiter le vieillissement de la peau et à réduire les rides.
PCT/EP2000/002999 1999-04-16 2000-04-05 Preparations pharmaceutiques ou cosmetiques pour l'application locale intradermique d'hormones Ceased WO2000062753A1 (fr)

Priority Applications (3)

Application Number Priority Date Filing Date Title
EP00926811A EP1171091A1 (fr) 1999-04-16 2000-04-05 Preparations pharmaceutiques ou cosmetiques pour l'application locale intradermique d'hormones
AU45432/00A AU4543200A (en) 1999-04-16 2000-04-05 Pharmaceutical or cosmetic compositions for the local, intradermal application of hormones
JP2000611890A JP2003527310A (ja) 1999-04-16 2000-04-05 エストロゲンを局部的に皮内投与するための医薬品組成物または化粧品組成物

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
DE19918644.8 1999-04-16
DE1999118644 DE19918644A1 (de) 1999-04-16 1999-04-16 Pharmazeutische Zusammensetzungen zur lokalen, intradermalen Applikation von Estrogenen
US13062499P 1999-04-26 1999-04-26
US60/130,624 1999-04-26

Publications (1)

Publication Number Publication Date
WO2000062753A1 true WO2000062753A1 (fr) 2000-10-26

Family

ID=26053065

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2000/002999 Ceased WO2000062753A1 (fr) 1999-04-16 2000-04-05 Preparations pharmaceutiques ou cosmetiques pour l'application locale intradermique d'hormones

Country Status (4)

Country Link
EP (1) EP1171091A1 (fr)
JP (1) JP2003527310A (fr)
AU (1) AU4543200A (fr)
WO (1) WO2000062753A1 (fr)

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003103685A1 (fr) * 2002-06-11 2003-12-18 Pantarhei Bioscience B.V. Methode de traitement de la peau humaine et composition pour le soin de la peau destinee a etre utilisee dans cette methode
US7732430B2 (en) 2001-05-23 2010-06-08 Pantarhei Bioscience B.V. Drug delivery system comprising a tetrahydroxilated estrogen for use in hormonal contraception
US7871995B2 (en) 2001-05-23 2011-01-18 Pantarhei Bioscience B.V. Drug delivery system comprising a tetrahydroxylated estrogen for use in hormonal contraception
US7923440B2 (en) 2002-06-11 2011-04-12 Pantarhei Bioscience B.V. Method of treating or preventing immune mediated disorders and pharmaceutical formulation for use therein
US8026228B2 (en) 2001-11-15 2011-09-27 Pantarhei Bioscience B.V. Estrogenic compounds in combination with progestogenic compounds in hormone-replacement therapy
US8048869B2 (en) 2001-05-18 2011-11-01 Pantarhei Bioscience B.V. Pharmaceutical composition for use in hormone replacement therapy
US8236785B2 (en) 2007-01-08 2012-08-07 Pantarhei Bioscience B.V. Method of treating or preventing infertility in a female mammal and pharmaceutical kit for use in such method
US9034854B2 (en) 2002-07-12 2015-05-19 Pantarhei Bioscience B.V. Pharmaceutical composition comprising estetrol derivatives for use in cancer therapy

Citations (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2350315A1 (de) * 1973-10-06 1975-04-17 Hahn Carl Dr Gmbh Pharmazeutische und kosmetische praeparate zur aeusserlichen anwendung
EP0186019A2 (fr) * 1984-12-22 1986-07-02 Schwarz Pharma Ag Pansement médicamenteux
EP0275716A1 (fr) * 1986-12-29 1988-07-27 Rutgers, The State University Of New Jersey Unité de dosage transdermique estrogène/progestine et ensemble contraceptif comprenant cette unité.
WO1991006289A1 (fr) * 1989-10-31 1991-05-16 Watson Laboratories, Inc. Support muco-adhesif servant a liberer un agent therapeutique
JPH04210610A (ja) * 1990-11-30 1992-07-31 Shiseido Co Ltd 皮膚外用剤組成物
DE4400770C1 (de) * 1994-01-13 1995-02-02 Lohmann Therapie Syst Lts Wirkstoffhaltiges Pflaster zur Abgabe von Estradiol mit mindestens einem Penetrationsverstärker, Verfahren zu seiner Herstellung und seine Verwendung
DE4416927C1 (de) * 1994-05-13 1995-08-31 Lohmann Therapie Syst Lts Vorrichtung zur Abgabe von Wirkstoffen aus Haftschmelzklebern, Verfahren zu ihrer Herstellung und ihre Verwendung
WO1996030000A1 (fr) * 1995-03-30 1996-10-03 Sanofi Composition pharmaceutique filmogene pour administration transdermique
DE19534209A1 (de) * 1995-09-15 1997-03-20 Jenapharm Gmbh Hormonales Mittel zur Behandlung der Haut
DE19634206A1 (de) * 1996-08-26 1998-03-05 Ludwig Dr Reinke Hautpflegemittel, insbesondere für alternde Haut
DE19652196A1 (de) * 1996-12-16 1998-06-18 Jenapharm Gmbh Homogene steroidhaltige Präformulierungen zur Herstellung niedrigdosierter fester und halbfester pharmazeutischer Zubereitungen
DE19701949A1 (de) * 1997-01-13 1998-07-16 Jenapharm Gmbh Transdermales therapeutisches System
WO1998031346A1 (fr) * 1997-01-16 1998-07-23 Massachusetts Institute Of Technology Preparation de particules pour inhalation
WO1999004748A2 (fr) * 1997-07-25 1999-02-04 Unilever Plc Composition pour soins de beaute

Patent Citations (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2350315A1 (de) * 1973-10-06 1975-04-17 Hahn Carl Dr Gmbh Pharmazeutische und kosmetische praeparate zur aeusserlichen anwendung
EP0186019A2 (fr) * 1984-12-22 1986-07-02 Schwarz Pharma Ag Pansement médicamenteux
EP0275716A1 (fr) * 1986-12-29 1988-07-27 Rutgers, The State University Of New Jersey Unité de dosage transdermique estrogène/progestine et ensemble contraceptif comprenant cette unité.
WO1991006289A1 (fr) * 1989-10-31 1991-05-16 Watson Laboratories, Inc. Support muco-adhesif servant a liberer un agent therapeutique
JPH04210610A (ja) * 1990-11-30 1992-07-31 Shiseido Co Ltd 皮膚外用剤組成物
DE4400770C1 (de) * 1994-01-13 1995-02-02 Lohmann Therapie Syst Lts Wirkstoffhaltiges Pflaster zur Abgabe von Estradiol mit mindestens einem Penetrationsverstärker, Verfahren zu seiner Herstellung und seine Verwendung
DE4416927C1 (de) * 1994-05-13 1995-08-31 Lohmann Therapie Syst Lts Vorrichtung zur Abgabe von Wirkstoffen aus Haftschmelzklebern, Verfahren zu ihrer Herstellung und ihre Verwendung
WO1996030000A1 (fr) * 1995-03-30 1996-10-03 Sanofi Composition pharmaceutique filmogene pour administration transdermique
DE19534209A1 (de) * 1995-09-15 1997-03-20 Jenapharm Gmbh Hormonales Mittel zur Behandlung der Haut
EP0765663A2 (fr) * 1995-09-15 1997-04-02 JENAPHARM GmbH Utilisation du diénogest pour la fabrication d'un médicament pour le traitement de la peau par application topique
DE19634206A1 (de) * 1996-08-26 1998-03-05 Ludwig Dr Reinke Hautpflegemittel, insbesondere für alternde Haut
DE19652196A1 (de) * 1996-12-16 1998-06-18 Jenapharm Gmbh Homogene steroidhaltige Präformulierungen zur Herstellung niedrigdosierter fester und halbfester pharmazeutischer Zubereitungen
DE19701949A1 (de) * 1997-01-13 1998-07-16 Jenapharm Gmbh Transdermales therapeutisches System
WO1998031346A1 (fr) * 1997-01-16 1998-07-23 Massachusetts Institute Of Technology Preparation de particules pour inhalation
WO1999004748A2 (fr) * 1997-07-25 1999-02-04 Unilever Plc Composition pour soins de beaute

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
PATENT ABSTRACTS OF JAPAN vol. 016, no. 552 (C - 1006) 20 November 1992 (1992-11-20) *

Cited By (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8048869B2 (en) 2001-05-18 2011-11-01 Pantarhei Bioscience B.V. Pharmaceutical composition for use in hormone replacement therapy
US7732430B2 (en) 2001-05-23 2010-06-08 Pantarhei Bioscience B.V. Drug delivery system comprising a tetrahydroxilated estrogen for use in hormonal contraception
US7871995B2 (en) 2001-05-23 2011-01-18 Pantarhei Bioscience B.V. Drug delivery system comprising a tetrahydroxylated estrogen for use in hormonal contraception
US8026228B2 (en) 2001-11-15 2011-09-27 Pantarhei Bioscience B.V. Estrogenic compounds in combination with progestogenic compounds in hormone-replacement therapy
WO2003103685A1 (fr) * 2002-06-11 2003-12-18 Pantarhei Bioscience B.V. Methode de traitement de la peau humaine et composition pour le soin de la peau destinee a etre utilisee dans cette methode
US7923440B2 (en) 2002-06-11 2011-04-12 Pantarhei Bioscience B.V. Method of treating or preventing immune mediated disorders and pharmaceutical formulation for use therein
US9040509B2 (en) 2002-06-11 2015-05-26 Pantarhei Bioscience B.V. Method of treating human skin and a skin care composition for use in such a method
US9034854B2 (en) 2002-07-12 2015-05-19 Pantarhei Bioscience B.V. Pharmaceutical composition comprising estetrol derivatives for use in cancer therapy
US10201611B2 (en) 2002-07-12 2019-02-12 Donesta Bioscience B.V. Pharmaceutical composition comprising estetrol derivatives for use in cancer therapy
US8236785B2 (en) 2007-01-08 2012-08-07 Pantarhei Bioscience B.V. Method of treating or preventing infertility in a female mammal and pharmaceutical kit for use in such method

Also Published As

Publication number Publication date
JP2003527310A (ja) 2003-09-16
AU4543200A (en) 2000-11-02
EP1171091A1 (fr) 2002-01-16

Similar Documents

Publication Publication Date Title
DE19739916C2 (de) Verwendung einer Kombination aus einem Gestagen und einem Estrogen zur kontinuierlichen Ovulationshemmung und ggf. gleichzeitigen Behandlung und/oder Prophylaxe von Tumoren der Brustdrüsen
DE69721377T2 (de) Arzneimittel zur transdermalen Verabreichung von einem Östrogen oder Progestin oder einer Mischung davon
DE69734114T2 (de) Topische zusammensetzung und verfahren zur verbesserung der lipidbarrieresynthese
EP0367103B1 (fr) Onguent topique
EP0765663A2 (fr) Utilisation du diénogest pour la fabrication d'un médicament pour le traitement de la peau par application topique
DE3411225C2 (fr)
EP1171091A1 (fr) Preparations pharmaceutiques ou cosmetiques pour l'application locale intradermique d'hormones
DE4038385C2 (de) Sitosterol und seine Glykoside mit verbesserter Bioverfügbarkeit
EP1347764B1 (fr) Gel a base d'alcool pour traiter l'hypogonadisme par voie trans-scrotale
EP1063998B1 (fr) Medicament contenant un inhibiteur steroidien de l'aromatase pour la prophylaxie et/ou le traitement du carcinome du sein
DE69228814T2 (de) Verfahren zur vorbeugung und behandlung von durch chemotherapie ausgelöster alopezie
DE69300854T2 (de) Mittel zur topischen Verabreichung von Spironolakton.
DD153759A5 (de) Haarpflegemittel zur aeusseren anwendung
DE4319096C1 (de) Hormonales Mittel zur Vorbeugung und Behandlung arterieller Erkrankungen beim Mann
DE4119170C2 (de) Mittel gegen Neurodermitis
DE19918644A1 (de) Pharmazeutische Zusammensetzungen zur lokalen, intradermalen Applikation von Estrogenen
DE69911955T2 (de) VERWENDUNG VON DANAZOL ZUR BEHANDLUNG VON HYPOGONADISMUS IN MÄNNERn
DE3020616C2 (fr)
EP0952833A1 (fr) Application topique d'androgene par voie penienne pour le traitement de la dyserection
DE2757024C3 (de) Kosmetisches Haar- und Hautpflegemittel
DE4010042A1 (de) Verwendung von efeu zur topischen behandlung vermehrter schuppenbildung der behaarten und unbehaarten haut sowie der psoriasis
DE69228112T2 (de) Verfahren zur verbesserung des gedächtnisses und zur steigerung der lebensqualitet
EP0630248A1 (fr) Utilisation d' striol pour traiter l'osteoporose climacterique
DE3915133C2 (de) Haarwuchsmittel
DE3829640C1 (fr)

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2000926811

Country of ref document: EP

ENP Entry into the national phase

Ref country code: JP

Ref document number: 2000 611890

Kind code of ref document: A

Format of ref document f/p: F

WWP Wipo information: published in national office

Ref document number: 2000926811

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 09958556

Country of ref document: US

WWW Wipo information: withdrawn in national office

Ref document number: 2000926811

Country of ref document: EP